Board of Directors
Susanne Høiberg, Dr., European Patent Attorney
Chairman
Dr. Susanne Høiberg is CEO, board member and Partner in the IP law firm Høiberg. Dr. Høiberg entered the IP profession in 1990 with a Copenhagen based intellectual property firm. Høiberg IP Law firm was founded by Dr. Høiberg in 1995. Dr. Høiberg specialises in patent portfolio strategy and innovation management within the areas of biotechnology, medicine and medico-technology with issues that range from prosecution globally, licensing, collaborations and technology acquisitions, patent validity and infringement. Dr. Høiberg graduated from medical school at University of Copenhagen in 1988, and worked as a medical doctor in Glostrup Hospital as well as cancer researcher before entering the IP field. Dr. Høiberg teaches IP in CEIPI Denmark and gives lectures and seminars on various IP issues. Dr. Høiberg is a member of the Danish Patent Agent Association, FICPI as well as the European Patent Institute.
|
|
Martin Bonde, Ph.D
Board Member
Dr. Martin Bonde is CEO of Epitherapeutics (www.epitherapeutics.dk) and has previously held senior positions in a number of biotech companies. While CEO at NatImmune from December 2004, he fronted several rounds of fundraisings and a significant licensing deal with Enzon Pharmaceuticals. He sold NatImmune to IPC International in June 2009. From January 2003 to December 2004, Dr. Bonde was CEO of Combio A/S. He sold Combio to Arpida AG, which IPO’ed in May 2005. From 2000-2002 he was Executive Vice President of CelTor Inc, a US biotech company. In 1998 Dr. Bonde founded Torsana Biosensor A/S and was its CEO until he sold the company to CelTor Inc in 2000. Dr. Bonde holds a PhD in chemical engineering from the Technical University of Denmark and a B. Comm. from Copenhagen Business School.
|
|
Thomas Weilby Knudsen, M. Sc.
Board Member
Thomas Weilby Knudsen is the managing partner of NorthCap Partners (www.northcappartners.com). He has been in venture capital since 2002. Prior to joining venture capital, Thomas Weilby Knudsen, has an operational background from ERP consulting, IT and telecoms, and held several senior management positions at TDC and Cybercity. Thomas Weilby Knudsen has extensive experience in establishing new businesses within Internet and telecom across Europe. Thomas Weilby Knudsen holds a M.Sc. degree in Economics (Finance and business administration) from University of Aarhus. Thomas Weilby Knudsen has board experience from TDC Hosting (eStructure), Kapow Technologies, Octoshape, Intelepeer, Nangate, among other IT companies.
|
|
Michael Grunkin, Ph.D
Board member and CEO
Dr. Michael Grunkin is founder and managing director of Visiopharm. He received his Ph.D in image analysis from the Technical University of Denmark in 1993. His post-doctoral work was carried out on Massachusetts Institute of Technology and Harvard Medical School, where he combined a strong theoretical and practical background in image analysis with applications from the life-sciences. From 1996, he was the technical founder of two Danish companies developing advanced image analysis technology for diagnosing osteoporosis and various diseases manifesting themselves on the human retina. In 2001, he co-founded Visiopharm, which is focused on the development of general as well as application-specific image analysis solutions for the life-sciences.
|
|
Niels Tækker Foged, M. Sc., DVS, B.Comm
Board member and CSO
Dr. Niels Tækker Foged joined Visiopharm in 2006 leaving a position as R&D Director of the world leading cancer diagnostics company Dako A/S. Dr. Foged is a master of science in chemistry, and holds a bachelor degree in financing. He achieved his title of doctor of veterinary science (DVS) by developing a recombinant vaccine and diagnostic method for an infectious disease in pigs. Before joining Dako in 2002, Dr. Foged was co-founder and CEO of the biotech company Osteopro A/S, which in a merger became a part of Nordic Bioscience A/S, a company developing pharmaceuticals and diagnostics for diseases of bone and cartilage.
|
|
|
